“Resistant to Resistance: Approaches to Address Resistance in Oncology” was moderated by Jennifer Kim and Kristen Kluska. It featured Dr. Weiguo Su, CEO & CSO of HUTCHMED, Dr. Troy Wilson, President & CEO of Kura Oncology, Inc., Dr. Tim Clackson, CEO of Theseus Pharmaceuticals, and Dr. Todd Harris, CEO of Tyra Biosciences.

• HUTCHMED’s development program includes 13 registrational studies for six drug candidates which could support potential near-term NDA filings through 2025; particular focus during the discussion was on late-stage global assets, fruquintinib and savolitinib.

• Kura Oncology is solely focused on precision oncology. It has programs spanning leukemia, head and neck cancer, lung cancer, and other solid tumors.

• Theseus is developing pan-variant tyrosine kinase inhibitors (TKIs), with the lead indication in a Phase 1/2 study for GIST.

• Tyra Biosciences is a precision oncology company focused on developing next-gen product candidates that target acquired resistance in oncology, including a pipeline of selective FGFR inhibitors (TYRA-300, TYRA-200).

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare